Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: October 18, 2024
Reporting Period: Events occurring on October 18, 2024, and October 24, 2024.
Business Overview: The Company is a Texas corporation reporting unregistered sales of equity securities and conversions of preferred stock.
Key Financial Metrics and Transactions
This filing details specific capital raising activities rather than comprehensive financial statements. Key transaction metrics include:
- Equity Purchase Agreement (ELOC): Under an agreement with Platinum Point Capital, the Company sold 33,333 shares of common stock on October 24, 2024.
- Proceeds from ELOC: Net proceeds were $78,787 (gross price $2.36 per share, net of fees, discounts, and expenses).
- Preferred Stock Conversion: On October 18, 2024, the Purchaser converted 200 shares of Series B Preferred Stock into 93,299 shares of common stock.
- Conversion Value: The converted shares were valued at $2.358 per share, totaling $220,000.
- Debt and Liquidity: The filing text does not provide clear values for total debt, cash flow, or overall liquidity positions.
Material Changes Versus Prior Period
The filing does not provide comparative financial data (e.g., revenue or profit margins) against prior periods. The material changes reported are:
- Execution of an "Advance Notice" under the ELOC, resulting in the issuance of 33,333 new common shares.
- Conversion of existing Series B Preferred Stock into common stock, increasing the outstanding common share count by 93,299 shares.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the Company's ability to direct the Purchaser to buy shares up to 100% of the average daily trading volume over the preceding five trading days during the 2-year commitment period.
Risks and Contingencies:
- Transfer Restrictions: The shares issued under the ELOC are subject to transfer restrictions and contain legends stating they are not registered under the Securities Act.
- Resale Limitations: Securities may not be offered or sold in the United States absent registration or an exemption.
- Valuation Mechanism: The purchase price for ELOC shares is determined by 90% of the gross proceeds received by the Purchaser during a three-day valuation period following the advance notice.
Important Facts for Investor Verification
- Verify the total number of outstanding common shares post-conversion and post-ELOC issuance to assess dilution.
- Confirm the remaining commitment amount available under the $25,000,000 ELOC with Platinum Point Capital.
- Review the specific terms of the Series B Preferred Stock conversion to understand future conversion triggers.
- Check the Company's cash balance to determine if the $78,787 net proceeds significantly impact short-term liquidity.